Literature DB >> 29114732

Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia.

Yujing Zhao1, Dana L Tudorascu2, Oscar L Lopez3,4, Ann D Cohen4, Chester A Mathis5, Howard J Aizenstein4, Julie C Price5,6, Lewis H Kuller7, M Ilyas Kamboh8, Steven T DeKosky9, William E Klunk3,4, Beth E Snitz3.   

Abstract

Importance: The prevalence of pathologic conditions of the brain associated with Alzheimer disease increases strongly with age. Little is known about the distribution and clinical significance of preclinical biomarker staging in the oldest old, when most individuals without dementia are likely to have positive biomarkers. Objective: To compare the patterns of long-term cognitive decline in multiple domains by preclinical biomarker status in the oldest old without dementia. Design, Setting, and Participants: A longitudinal observational study with a mean (SD) of 12.2 (2.2) years (range 7.2-15.1 years) of follow-up was conducted in an academic medical center from August 24, 2000, to January 14, 2016, including and extending observations from the Ginkgo Evaluation of Memory study. A total of 197 adults who had completed the Ginkgo Evaluation of Memory study, were free of dementia, and were able to undergo magnetic resonance imaging were eligible for a neuroimaging study in 2009. Of these patients, 175 were included in the present analyses; 140 (80%) were cognitively normal and 35 (20%) had mild cognitive impairment. Main Outcomes and Measures: Biomarker groups included amyloid β negative (Aβ-)/neurodegeneration negative (ND-), amyloid β positive (Aβ+)/ND-, Aβ-/neurodegeneration positive (ND+), and Aβ+/ND+ based on Pittsburgh Compound B retention and hippocampal volume in 2009. Participants completed baseline neuropsychological testing from 2000 to 2002 and annual testing from 2004 to 2016. Domains included memory, executive function, language, visual-spatial reasoning, and attention and psychomotor speed. Slopes of decline were evaluated with linear mixed models adjusted for age, sex, and years of education.
Results: Of the 175 participants (71 women and 104 men), at imaging, mean (SD) age was 86.0 (2.9) years (range, 82-95 years). A total of 42 participants (24.0%) were Aβ-/ND-, 32 (18.3%) were Aβ+/ND-, 35 (20.0%) were Aβ-/ND+, and 66 (37.7%) were Aβ+/ND+. On all cognitive measures, the Aβ+/ND+ group showed the steepest decline. Compared with the Aβ-/ND- group, the amyloid deposition alone (Aβ+/ND-) group showed faster decline on tests of verbal and visual memory (-0.3513; 95% CI, -0.5269 to -0.1756), executive function (0.0158; 95% CI, 0.0013-0.0303), and language (-0.1934; 95% CI, -0.3520 to -0.0348). The Aβ-/ND+ group showed faster visual memory decline than the Aβ-/ND- reference group (-0.3007; 95% CI, -0.4736 to -0.1279). Conclusions and Relevance: In the oldest old without dementia, presence of either or both Aβ and hippocampal atrophy is typical (>75%). Isolated hippocampal volume atrophy is associated only with greater decline in memory. However, isolated Aβ is associated with decline in memory plus language and executive functions. These findings suggest different underlying pathophysiologic processes in the Aβ+/ND- and Aβ-/ND+ groups.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29114732      PMCID: PMC5833487          DOI: 10.1001/jamaneurol.2017.3029

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  49 in total

1.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

Authors:  Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan
Journal:  Lancet Neurol       Date:  2013-09-04       Impact factor: 44.182

2.  Ecology of the aging human brain.

Authors:  Joshua A Sonnen; Karen Santa Cruz; Laura S Hemmy; Randall Woltjer; James B Leverenz; Kathleen S Montine; Clifford R Jack; Jeffrey Kaye; Kelvin Lim; Eric B Larson; Lon White; Thomas J Montine
Journal:  Arch Neurol       Date:  2011-08

3.  Cognitive Decline in Preclinical Stage 2 Alzheimer Disease and Implications for Prevention Trials.

Authors:  Elizabeth C Mormino; Kathryn V Papp
Journal:  JAMA Neurol       Date:  2016-06-01       Impact factor: 18.302

4.  Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration?

Authors:  J L Whitwell; C R Jack; J E Parisi; M L Senjem; D S Knopman; B F Boeve; R Rademakers; M Baker; R C Petersen; D W Dickson; K A Josephs
Journal:  Neurology       Date:  2010-12-14       Impact factor: 9.910

5.  The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly.

Authors:  Miranka Wirth; Hwamee Oh; Elizabeth C Mormino; Candace Markley; Susan M Landau; William J Jagust
Journal:  Alzheimers Dement       Date:  2013-03-07       Impact factor: 21.566

6.  Ginkgo biloba for prevention of dementia: a randomized controlled trial.

Authors:  Steven T DeKosky; Jeff D Williamson; Annette L Fitzpatrick; Richard A Kronmal; Diane G Ives; Judith A Saxton; Oscar L Lopez; Gregory Burke; Michelle C Carlson; Linda P Fried; Lewis H Kuller; John A Robbins; Russell P Tracy; Nancy F Woolard; Leslie Dunn; Beth E Snitz; Richard L Nahin; Curt D Furberg
Journal:  JAMA       Date:  2008-11-19       Impact factor: 56.272

7.  Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study.

Authors:  Clifford R Jack; Heather J Wiste; Stephen D Weigand; Walter A Rocca; David S Knopman; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Gregory M Preboske; Vernon S Pankratz; Prashanthi Vemuri; Ronald C Petersen
Journal:  Lancet Neurol       Date:  2014-09-04       Impact factor: 44.182

8.  Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old.

Authors:  Oscar L Lopez; William E Klunk; Chester Mathis; Rhaven L Coleman; Julie Price; James T Becker; Howard J Aizenstein; Beth Snitz; Ann Cohen; Milos Ikonomovic; Eric McDade; Steven T DeKosky; Lisa Weissfeld; Lewis H Kuller
Journal:  Neurology       Date:  2014-10-10       Impact factor: 9.910

9.  Frequent amyloid deposition without significant cognitive impairment among the elderly.

Authors:  Howard Jay Aizenstein; Robert D Nebes; Judith A Saxton; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Scott K Ziolko; Jeffrey A James; Beth E Snitz; Patricia R Houck; Wenzhu Bi; Ann D Cohen; Brian J Lopresti; Steven T DeKosky; Edythe M Halligan; William E Klunk
Journal:  Arch Neurol       Date:  2008-11

10.  Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration.

Authors:  Clifford R Jack; Heather J Wiste; David S Knopman; Prashanthi Vemuri; Michelle M Mielke; Stephen D Weigand; Matthew L Senjem; Jeffrey L Gunter; Val Lowe; Brian E Gregg; Vernon S Pankratz; Ronald C Petersen
Journal:  Neurology       Date:  2014-04-04       Impact factor: 9.910

View more
  14 in total

1.  Longitudinal evaluation of surrogates of regional cerebral blood flow computed from dynamic amyloid PET imaging.

Authors:  Murat Bilgel; Lori Beason-Held; Yang An; Yun Zhou; Dean F Wong; Susan M Resnick
Journal:  J Cereb Blood Flow Metab       Date:  2019-02-12       Impact factor: 6.200

2.  The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies.

Authors:  Eider M Arenaza-Urquijo; Scott A Przybelski; Timothy L Lesnick; Jonathan Graff-Radford; Mary M Machulda; David S Knopman; Christopher G Schwarz; Val J Lowe; Michelle M Mielke; Ronald C Petersen; Clifford R Jack; Prashanthi Vemuri
Journal:  Brain       Date:  2019-04-01       Impact factor: 13.501

3.  The vascular risk factors and vascular neuropathology in subjects with autopsy-confirmed dementia with Lewy bodies.

Authors:  Zhi-Chao Chen; Jinghuan Gan; Yaqi Yang; Qingbo Meng; Jiuyan Han; Yong Ji
Journal:  Int J Geriatr Psychiatry       Date:  2022-03       Impact factor: 3.850

4.  Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.

Authors:  Murat Bilgel; Yang An; Jessica Helphrey; Wendy Elkins; Gabriela Gomez; Dean F Wong; Christos Davatzikos; Luigi Ferrucci; Susan M Resnick
Journal:  Brain       Date:  2018-08-01       Impact factor: 13.501

Review 5.  Neuroimaging in the Oldest-Old: A Review of the Literature.

Authors:  Davis C Woodworth; Kiana A Scambray; María M Corrada; Claudia H Kawas; S Ahmad Sajjadi
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

6.  Peripheral inflammatory biomarkers predict the deposition and progression of amyloid-β in cognitively unimpaired older adults.

Authors:  Lauren E Oberlin; Kirk I Erickson; Rachel Mackey; William E Klunk; Howard Aizenstein; Brian J Lopresti; Lewis H Kuller; Oscar L Lopez; Beth E Snitz
Journal:  Brain Behav Immun       Date:  2021-03-15       Impact factor: 19.227

7.  Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality.

Authors:  Oscar L Lopez; James T Becker; YueFang Chang; William E Klunk; Chester Mathis; Julia Price; Howard J Aizenstein; Beth Snitz; Ann D Cohen; Steven T DeKosky; Milos Ikonomovic; M Ilyas Kamboh; Lewis H Kuller
Journal:  Neurology       Date:  2018-04-25       Impact factor: 9.910

8.  Association Between Visual Memory and In Vivo Amyloid and Tau Pathology in Preclinical Autosomal Dominant Alzheimer's Disease.

Authors:  Yamile Bocanegra; Joshua T Fox-Fuller; Ana Baena; Edmarie Guzmán-Vélez; Clara Vila-Castelar; Jairo Martínez; Heirangi Torrico-Teave; Francisco Lopera; Yakeel T Quiroz
Journal:  J Int Neuropsychol Soc       Date:  2020-08-07       Impact factor: 2.892

9.  Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults.

Authors:  Tengfei Guo; Susan M Landau; William J Jagust
Journal:  Neurology       Date:  2020-03-18       Impact factor: 11.800

10.  Pathological correlates of impaired self-awareness of memory function in Alzheimer's disease.

Authors:  Geoffroy Gagliardi; Madeline Kuppe; Cristina Lois; Bernard Hanseeuw; Patrizia Vannini
Journal:  Alzheimers Res Ther       Date:  2021-06-25       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.